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Abstract
Background: Smear-negative pulmonary tuberculosis (SN-PTB), which is common in HIV-infected patients,
is difficult to diagnose using smear microscopy alone. In 2007, the WHO developed an algorithm to improve the
diagnosis and management of smear-negative tuberculosis in HIV prevalent and resource constrained settings.
Implementation of the algorithm required individuals with presumptive TB to be initially evaluated using two
sputum microscopy examinations followed by clinical diagnosis that may include chest X-ray and antibiotic
treatment in smear-negative individuals. Since that time, the WHO has endorsed several new tests for diagnosis of
tuberculosis. However, it is unclear how the new tests perform when compared to the WHO 2007 algorithm in
diagnosis of SN-PTB. Using meta-analysis study design, we summarized and compared the accuracy of Xpert®
MTB/Rif assay (GeneXpert) and Microscopic Observation Drug Susceptibility assay (MODS), with the WHO 2007
algorithm in the diagnosis of SN-PTB.
Methods: A systematic review and meta-analysis of publications on GeneXpert, or MODS, or the WHO 2007
algorithm for diagnosis of SN-PTB, using culture as reference test was performed. Meta-Disc software was used to
obtain pooled sensitivity and specificity of the diagnostic methods. Heterogeneity in the accuracy estimates was
tested by reviewing the generated forest plots, sROC curves and the Spearman correlation coefficient of the logit of
true positive rate versus the logit of false positive rate.
Results: Twenty-four publications on all three diagnostic methods were meta-analyzed. The pooled sensitivity and
specificity for detection of smear-negative pulmonary tuberculosis were 67% and 98% for GeneXpert, 73% and 91%
for MODS, and 61% and 69% for WHO 2007 algorithm, respectively. The sensitivity of GeneXpert reduced from 67%
to 54% when sub-group analysis of studies with patient HIV prevalence ≥30% was performed.
Conclusion: The GeneXpert, MODS, and the WHO algorithm have moderate to high accuracy for the diagnosis of
SN-PTB. However, the accuracy of the tests is extremely variable. The setting and context under which the tests are
conducted in addition to several other factors could explain this variability. There is therefore need to investigate
these factors further. The information from these studies would inform the adoption and placement of these new
tests.
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Background
The global burden of tuberculosis (TB) remains high with
8.7 million new TB cases estimated to have occurred in
2012 [1]. The majority of the new TB cases (80%) occurred
in 22 countries and a substantial proportion (35%) were
smear-negative pulmonary TB (SN-PTB). In these coun-
tries, TB diagnosis relies mainly on smear microscopy
which has a highly variable sensitivity ranging from 20%
to 60% [2,3]. In sub Saharan Africa, where the preva-
lence of 44 HIV is relatively high and TB is a common
opportunistic 45 infection, TB/HIV co-infected patients
frequently present with SN-PTB. This is because HIV
patients usually form poor lung granulomas/cavities
when infected with TB, resulting in lower concentra-
tions of Mycobacterium tuberculosis (Mtb) in the
lesions [4], which can pose diagnostic difficulties [5].
In 2007, the WHO issued an algorithm for the diagnosis
of SN-PTB for use in resource-limited settings with
high HIV infection rates [6]. Adoption of this algo-
rithm (Figure 1), was expected to improve diagnosis and
management of smear-negative tuberculosis. However, the
diagnostic methods used when the algorithm was made,
have since then been improved upon or entirely new tests
have been developed. The WHO has also endorsed several
of these new tests [7]. Further, the WHO 2007 algorithm
outlines a lengthy diagnostic pathway which requires a pa-
tient to visit the clinic four times before a clinician decides
whether to treat a patient as a case of smear-negative tuber-
culosis. In practice, few patients complete all the elements
of the algorithm (see Figure 1) before a decision to treat or
not is taken [8]. In addition, although the algorithm encour-
ages sputum culture during the second clinic visit to assist
the confirmation of diagnosis of smear-negative TB, this is
often not practically possible. Reasons for this include firstly
that the commonly available TB culture method in many of
the focus settings is the Lowenstein-Jensen (LJ) method, a
solid based medium that takes several weeks to detect bac-
terial growth. Secondly, in many of the countries for which
the algorithm was developed, culture facilities are often
limited to reference laboratories with insufficient capacity
Figure 1 WHO 2007 algorithm for the diagnosis of TB in ambulatory HIV-positive patients. a) the danger signs include any one of:
respiratory rate > 30/minute, fever > 39°C, pulse rate > 120/min and unable to walk unaided. b) for countries with adult HIV prevalence rate = 1%
or prevalence rate of HIV among tuberculosis patients = 5%. c) In the absence of HIV testing, classifying HIV status unknown as HIV-positive
depends on clinical assessment or national and/or local policy. d) AFB-positive is defined at least one positive and AFB-negative as two or more
negative smears. e) CPT = Co-trimoxazole preventive therapy. f) HIV assessment includes HIV clinical staging, determination of CD count if
available and referral for HIV care. g) the investigations within the box should be done at the same time wherever possible in order to decrease
the number of visits and speed up the diagnosis. h) antibiotics (except fluoroquinolones) to cover both typical and atypical bacteria should be
considered. i) PCP: Pneumocystis carinii pneumonia, also known as Pneumocystis jirovecii pneumonia. j) advise to return for reassessment if
symptoms recur.
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to meet the national demand for culture confirmation [1].
Because of the reasons mentioned above among others,
there has been limited success in improving diagnosis of
smear-negative TB using the algorithm.
More recently, the WHO endorsed the Xpert® MTB/Rif
assay (GeneXpert) for the diagnosis of TB [9]. The
GeneXpert relies on DNA-PCR technique for detection of
TB and Rifampicin resistance related mutations simultan-
eously. It is the first molecular assay for TB detection to be
fully automated and to integrate all the steps required for
PCR-based DNA test. It gives results within 3 hours. The
test has also been reported to be highly accurate for diagno-
sis of pulmonary TB [10]. Patients with presumptive HIV-
associated TB who are negative on smear examination are
the most likely to benefit from GeneXpert [11].
Another new test is the Microscopic Observation Drug
Susceptibility assay (MODS). The WHO recently endorsed
the test for rapid screening of multidrug-resistant TB
[12]. The MODS relies on two well-known properties
of M.tb i.e. (i) the rate of growth of M.tb in liquid medium
is considerably quicker than on solid medium(ii) the
morphology of M.tb in liquid culture is characteristic
and recognizable, consisting of so called “cord” like
structures [13]. Thus by using an inverted light micro-
scope to examine tissue culture plates inoculated with
sputum, M.tb growth can be detected within 7–10 days,
compared to conventional solid culture that takes several
weeks [14]. In settings where conventional culture services
for diagnosis of TB are not readily available, the MODS
could be an alternative for early diagnosis of SN-PTB
since it is simple, rapid and cheap.
However, evidence on the performance of the GeneXpert,
MODS assay, and the WHO 2007 algorithm for diagnosis
of SN-PTB is scanty. In this study, we did a meta-analysis
to summarize and compare the accuracy (sensitivity and
specificity) of the GeneXpert (a molecular based assay),
the MODS (a rapid culture method) and the WHO 2007
algorithm (an algorithm based method) for the diagnosis
of SN-PTB. We considered all the elements of the WHO
2007 algorithm (its entirety) as one test.
Methods
Study design
A systematic review of publications on GeneXpert, MODS
and the WHO 2007 algorithm for the diagnosis of SN-PTB
was performed, followed by a meta-analysis.
Search strategy
Initially, we performed an electronic search in Pubmed
without year restriction for articles in English for each
test individually. The search terms used were ‘GeneXpert’,
‘Microscopic observation drug susceptibility’, and ‘WHO
TB algorithm’. We then reviewed the retrieved abstracts
and selected publications for full text review. After fully
reading the selected publications, their bibliographies
were also reviewed and relevant additional publications
were also retrieved for full text review. To ensure that
no relevant publications were missed, we also performed a
search in Google Scholar, but no additional publications
were found.
Inclusion
We selected peer-reviewed articles published until
30th May 2012. The publications should have used the
GeneXpert, or MODS, or WHO 2007 algorithm, for
diagnosis of pulmonary TB. The inclusion criteria were:
i) use of culture as the reference method (LJ, or 7H10
agar, or BACTEC 460, or BACTEC MGIT 960). ii) Pub-
lications should have reported data to allow first hand
computation of sensitivity and specificity of the test for
SN-PTB. In papers where this was not reported, we con-
tacted the corresponding authors to request provision
of the required data.
Data extraction
We created an excel spreadsheet and collected data on
20 variables per article, including: index test, author and
year of publication, culture method, country of study,
study HIV prevalence, sample size, specimen type, culture
method, and numbers of true positive, true negative, false
positive, and false negative. Numbers of the positive and
negative values were extracted either directly or through
calculation based on reported measures of accuracy. The
obtained data were verified by a second investigator.
Assessment of quality of study publications
Publications included in the meta-analysis were assessed
for quality using the QUADAS-2 tool [15]. The tool con-
sists of four key domains that judge bias and applicability
of the reviewed studies by reviewing how patients were se-
lected, the index test, the reference standard, and the flow
of patients through the study. These variables were also
included in the main data excel spreadsheet.
Data analysis
From the main spreadsheet we created sub files for Gen-
eXpert, MODS and the WHO 2007 algorithm. Each file
was configured to fit into the Meta-Disc software v.1.4
for data analysis [16]. Using the random-effects model,
the accuracy of each diagnostic method was analyzed
and presented in form of forest plots. We used the forest
plots to obtain a general overview of the accuracy esti-
mates of each study before subsequent interpretation of
the pooled summary estimates. Sensitivity was defined
as the proportion of positive results obtained while spe-
cificity was defined as the proportion of negative results
obtained, for each diagnostic method in reference to
culture. For one of the publications on the WHO 2007
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algorithm [8], we analyzed and reported the results sep-
arately. This is because the authors aimed to evaluate
the effect of various patient and provider factors on the
performance of the algorithm in a rural versus urban
setting. They therefore reported the diagnostic perform-
ance of the algorithm at the two sites separately but in
one publication.
Analysis for heterogeneity
As study results can be variable (heterogeneous), it is
critical to explore this heterogeneity to understand the
possible factors that influence the obtained accuracy
estimates and whether it is appropriate to pool them.
Heterogeneity can either be due to chance or due to
differences in the threshold that is used to define positive
and negative results of a test.
We explored for heterogeneity due to chance (other than
threshold effect) for each diagnostic method by; i) visual
inspection of the forest plots for deviation of sensitivity and
specificity of each study from the vertical line correspond-
ing to the pooled estimates. Large deviations from this line
would indicate possibility of heterogeneity, (ii) Chi-square
p-values, which are automatically computed by Meta-disc
during analysis. A low Chi-square p-value would suggest
presence of heterogeneity beyond what could be expected
by chance alone and, (iii) the inconsistence index (I-square),
which is also automatically computed by Meta-disc soft-
ware. The inconsistence index is a quantitative measure
of the amount of heterogeneity [17]. We interpreted the
inconsistence index as follows: 0% to 40%: not important;
50% to 70%: represented moderate heterogeneity; > 70%
represented substantial heterogeneity [18].
Heterogeneity due to threshold effect was explored by
plotting summary receiver operating curves (sROC) for
each diagnostic method to assess if the points in the plots
had a curvilinear (shoulder arm) pattern or not. A typical
“shoulder arm” pattern would suggest presence of thresh-
old effect [16,19,20]. The Meta-disc software automatically
computes and shows the statistical analysis of the area
under the sROC curve and the Cochrane indices (Q*). As
a further assessment of threshold effect, we also calculated
the Spearman correlation coefficient between sensitivity
(logit of the true positive rate) and specificity (logit of the
false positive rate) for each test. If threshold effect exists,
an inverse correlation appears. We considered a positive
Spearman correlation coefficient of > 0.6 to be strong, and
suggestive of threshold effect [21]. If the value was less than
0.6, the accuracy of the tests could be based on pooled esti-
mates of sensitivity and specificity.
Results
Publications retrieved
The systematic review based on all the stated strategies
retrieved a total of 256 abstracts. After reviewing the
abstracts, 125 publications (WHO algorithm 18, MODS
66 and GeneXpert 41) were fully reviewed. Due to various
reasons such as; a test not being evaluated for diagnostic
accuracy or data to allow computation of sensitivity
and specificity not reported (see Figure 2), 101 publica-
tions were excluded leaving twenty-four publications
for final meta-analysis (GeneXpert-15, MODS-5, and
WHO 2007 algorithm-4).
Description of meta-analyzed publications
Of the 24 publications that fulfilled the inclusion criteria for
meta-analysis, the study HIV prevalence in 9 of them
was ≥50% (GeneXpert-4, MODS-2, WHO 2007 algorithm-3).
In addition, 10 of the 24 publications were conducted
in countries from sub-Saharan Africa (GeneXpert-6,
MODS-1, and WHO 2007 algorithm-3). Further, 6 out
of 15 publications on GeneXpert used fluorescent mi-
croscopy (FM) as the screening test, while 3 out of 5
publications on MODS used Ziehl-Nielsen microscopy
(ZN) as the screening test, and 2 out of 4 publications
on the WHO 2007 algorithm used either FM or ZN. A
summary of the description of the studies meta-analyzed
is presented in Table 1.
Results on diagnostic accuracy
The results of the sensitivity and specificity of each test
are shown in Figure 3. Overall, there was large deviation
from the pooled estimates in the forest plots for all the
three tests indicating the possibility of heterogeneity.
However, the deviation was seen more with forest plots
for sensitivity than specificity. The Chi-square p-values
for heterogeneity for all three tests were low.
GeneXpert
The pooled sensitivity and the 95% confidence interval
for GeneXpert was 67% (62% to 71%) while the pooled
specificity was 98% (97% to 99%). On visualization of
the forest plots, there was large deviation from the
pooled estimate for sensitivity by several studies. For
specificity, deviation from the pooled estimate was small.
However, the I-square values for both sensitivity and
specificity were above 40%.
MODS
The pooled sensitivity and the 95% confidence interval for
the MODS test was73% (66% to 79%) while the pooled
specificity was 91% (92% to 96%). On visualization of the
forest plots, there was large deviation from the pooled
estimate for sensitivity by two studies. For specificity,
large deviation from the pooled estimate observed for
one study. The I-square values for both sensitivity and
specificity were above 70%.
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WHO 2007 algorithm
The pooled sensitivity and the 95% confidence interval for
the WHO 2007 algorithm was 61% (55% to 67%) while the
pooled specificity was 69% (66% to 72%). On visualization
of the forest plots, there was large deviation from the
pooled estimate for both sensitivity and specificity by
two studies. The I-square values for both sensitivity and
specificity were also above 70%.
Analysis for threshold effect by summary receiver
operating curves (sROC)
The patterns of the sROC curves are shown in Figure 4.
The curves were consistent with each of the included
reports of accuracy, with one outlier point (study) clearly
detected in the sROC curve for MODS. The areas under
the sROC curves and Cochrane (Q*) indices were 0.94 and
0.87 for GeneXpert, 0.87and 0.81 for MODS, 0.69 and 0.64
for WHO 2007 algorithm, respectively.
Spearman rank correlation for analysis of threshold effect
The Spearman rank correlations between the logistic
transformations (logit) of the true positive rate (TPR)
plotted against the logit of the false positive rate (FPR) for
each method is presented in Table 2. Only the WHO 2007
algorithm had a significant and strong positive correlation
coefficient of threshold effect.
Sub-group analysis
Having found indication of possible heterogeneity, we
performed the following sub-group analyses.
Based on HIV prevalence
For the GeneXpert, we focused on publications of studies
in settings with HIV prevalence ≥ 30%, a typical value
for TB patients from sub-Saharan Africa, where the
GeneXpert is expected to be of much benefit due to the
high levels of HIV-associated TB [9]. There were four
publications, from such high HIV prevalence settings;
two from South Africa and two from Tanzania, which we
sub- analyzed. The pooled sensitivity of the GeneXpert
from these settings was reduced from 67% to 54%, while
the specificity remained 99%. These results are presented
in Figure 5. For the WHO algorithm, a similar sub-group
analysis gave a sensitivity of 65% and a specificity of 55%.
We did not perform a similar sub-analysis for the MODS
because the publications were inadequate for the analysis.
Instead, we performed a sub-group analysis, excluding
the outlier study which had reported what the authors
Figure 2 Flow chart for publication search. * One of the WHO publications provided separate diagnostic accuracy results for a rural and
urban site. The results were therefore reported separately in Table 1. SNPTB = Smear-negative Pulmonary TB. Two landmark studies on
GeneXpert were excluded [22,23]. We contacted the author but the data provided remained incomplete to fill 2x2 tables for smear-negative
PTB (SNPTB).
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decsribed as “ unexplained observed disturbing incon-
sistencies in results”, when they used the MODS for
diagnosis of smear-negative TB [40]. Pooled sensitivity
of MODS increased from 73% to 82%, and specificity
increased from 91% to 95%.
Based on screening tests used
Since FM microscopy is increasingly becoming an alter-
native to ZN microscopy for diagnosis of TB in several
settings [48], we also performed subgroup analysis for
studies that used FM versus ZN as screening tests. The
sensitivity for GeneXpert for studies that used FM as
screening test was 52% and specificity was 98%. For studies
that used ZN the sensitivity for GeneXpert was 69% and
specificity was 99%. None of the studies evaluating MODS
used FM as a screening test, thus a similar sub-analysis
was not possible. However, the sensitivity for studies
that evaluated MODS using ZN as screening test was 73%,
while the specificity was 90%. There were an inadequate
number of studies that evaluated WHO 2007 algorithm
Table 1 Key characteristics of the meta-analyzed reports (n = 24)
Test Author, (Year) Ref Country Study HIV rate Specimen type Screen test TP FP FN TN
GeneXpert Helb, 2010 [24] Vietnam 1 Sputum frozen Unclear 38 0 15 25
Malbruny, 2011 [25] France 3.4 Various FM 6 0 0 73
Bowles, 2011 [26] Netherlands NR Sputum ZN 21 0 4 23
Moure, 2011 [27] Spain NR Sputum frozen FM + ZN 61 0 17 20
Marlowe, 2011 [28] USA NR Sputum sediment Unclear 43 0 12 47
Theron, 2011 [29] S. Africa 27 Sputum FM 22 19 25 319
Rachow, 2011 [30] Tanzania 59.9 Sputum frozen ZN 11 1 7 102
Scott, 2011 [31] S. Africa 70* Sputum sediment FM 11 3 7 104
Lawn, 2011 [32] S. Africa 100 Sputum FM 23 2 30 320
Ioannidis, 2011 [33] Greece NR Sputum Unclear 29 2 3 32
Miller, 2011 [34] USA NR Sputum frozen FM 3 2 2 58
Teo, 2011 [35] Singapore NR Various ZN 13 2 6 42
Nicol, 2011 [36] S. Africa 24 Sputum-induced FM 25 0 18 166
Rachow, 2012 [37] Tanzania 51.2 Sputum ZN 14 0 7 22
Safianowska, 2012 [38] Poland NR Various ZN 4 0 4 181
Total 324 31 157 1534
MODS Arias, 2007 [39] Brazil / Honduras 12* Various ZN 75 28 8 469
Mashta, 2011 [40] India NR Sputum ZN 17 45 27 146
Shah, 2011 [41] S. Africa 87 Sputum Unclear 36 13 14 407
Ha DT, 2010 [42] Vietnam 100 Sputum ZN 40 0 15 67
Chaiyasirinroje, 2012 [43] Thailand NR Sputum Unclear 13 1 4 37
Total 181 87 68 1126
WHO 2007 algorithm Wilson, 2011 [44] S. Africa 57* Sputum-induced FM 47 91 12 71
Swai, 2011 [45] Tanzania 68.1 Sputum ZN 66 107 61 179
Koole, 2012 [46] Cambodia 26.5 Sputum FM 20 70 14 270
Alamo, 2012. Rural site [8] Uganda 100 Sputum ZN 18 2 1 1
Alamo, 2012. Urban site [8] Uganda 100 Sputum ZN 9 13 1 10
Total 160 283 89 531
Specimen type various included = bronchial aspirate, bronchial alveolar lavage.
ZN = Ziehl-Nielsen microscopy stain method.
FM = Fluorescent microscopy stain method.
TP = True positive (Individuals have disease and have positive test).
FP = False positive (Individuals do not have disease, but have positive test).
FN = False negative (Individuals have disease, but have negative test).
TN = True negative (Individuals do not have disease and have negative test).
NR = Not reported.
* = The rate reported was based on a denominator that included patients with undocumented HIV result.
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Figure 3 Forest plots of sensitivity and specificity for (a) GeneXpert test, (b) MODS test and (c) WHO 2007 algorithm.
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using FM as a screening test. However, for those studies
that used ZN as the screen test, the sensitivity was 60%
and the specificity was 61%.
Based on patients not completing all elements of the WHO
2007 algorithm
Lastly, since the WHO 2007 algorithm is widely used for
diagnosis of smear-negative TB, but in practice few patients
complete all the elements of the algorithm before clinicians
exclude or initiate treatment for smear-negative TB, we
performed a sub-group analysis of the WHO algorithm,
excluding the publication that reported performance
Sensitivity SROC Curve
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Figure 4 Summary receiver characteristics (sROC) (a) curve- GeneXpert, (b) curve- MODS and (c) curve- WHO 2007 algorithm.
Note: sROC = summary receiver operating characteristic curve, which is a plot of the true positive rate (sensitivity) against the false positive rate
(1-specificity) of a diagnostic test at different thresholds [47]. This generates a composite statistic (AUC or the Index Q*) that provides an overall
evaluation of the accuracy of a test (perfect discriminating ability of true positivity from false positivity). The three curves of the sROC represent
the estimate and the 95% upper and lower bounds of the estimate. AUC = Area under the curve of a constructed sROC curve. An AUC close to
1.0 signifies that the test has almost perfect discrimination while an AUC close to 0.5 suggests poor discrimination. An AUC significantly less than
0.5 would indicate that the criteria for “normal” and “abnormal” should be reversed. SE (AUC) = standard error of the area under curve Q* = An
index which corresponds to the upper most point on the sROC curve at which sensitivity equals specificity. The closer this value is to 1,
the closer the test to perfect accuracy (perfect discriminating ability of true positivity from false positivity). When the value of the Q* index is
close to 0.5, it signifies that the test has poor discrimination. SE (Q*) = the standard error of the index Q*.
Table 2 Spearman correlation coefficient of the logit of
TPR versus logit of FPR
Test Spearman correlation coefficient p- value
GeneXpert 0.232 0.405
MODS 0.4 0.600
WHO 2007 algorithm 0.9 0.037
Note: The logit of the true positive rate is the natural log of [true positive
rate/(1-true positive rate)]. The logit of the false positive rate is the natural log
of [false positive rate/(1-false positive rate)].
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of the algorithm based on data of those patients that
completed all the elements of the algorithm before cli-
nicians decided if to treat or not [8]. The pooled sensi-
tivity of the WHO algorithm reduced from 61% to
57%, while specificity increased marginally from 69%
to 70% (data not shown).
QUADAS results of meta-analyzed publications
Seventeen out of the 24 meta-analyzed publications
(70%) had a low risk of bias. Of the publications at risk
of bias, six were on GeneXpert, while one was on WHO
2007 algorithm. The source of risk in these publications
arose principally from unclear and flow of patients.
However, all the publications matched the review ques-
tions, and therefore had low concern for applicability.
The overall quality of the 24 publications is shown in
Figure 6, while the quality of for the individual studies
are shown in Table 1.
Discussion
We set out to compare the accuracy of GeneXpert,
MODS and the WHO 2007 algorithm, for diagnosis of
SN-PTB by doing a meta-analysis of the published lit-
erature. To our knowledge, this is the first study done
to compare the accuracy of the three methods for the
diagnosis of SN-PTB.
Overall, the MODS had the highest pooled sensitivity
of 73%, followed by the GeneXpert with sensitivity of
67% and the WHO 2007 algorithm with sensitivity of 61%.
GeneXpert had the highest pooled specificity of 98%,
followed by MODS with 91% and the WHO 2007 algo-
rithm with 69%.
There was substantial heterogeneity in the accuracy
estimates for all the three tests that we evaluated, with
the inconsistence indices (I2) ranging from 71% to 90%
for sensitivity, and 70% to 93% for specificity. Considering
the sROC curves in view of the substantial heterogeneity,
the GeneXpert had the highest accuracy for detection of
SN-PTB with an area under the curve of a constructed
sROC curve (AUC) value of 0.94, followed by MODS with
0.88 and the WHO algorithm with 0.69.
Several reasons can explain the heterogeneity that we
observed. These include; variations in the HIV preva-
lence among study patients and the corresponding vari-
ation in the severity of TB disease. Additionally use of
either FM or ZN as the screening test including operator/
technician performance, type of specimen tested, and
differences in the culture methods used as reference
test can explain the variability.
Thus, the observed heterogeneity for the GeneXpert
could be due to differences in the severity of HIV and
the co-morbidities among the patients evaluated, since
the test is fully automated after sample processing, re-
quiring no technician involvement. On the other hand,
technician performance could be a major factor in the
heterogeneity observed for MODS, since inexperienced
technicians could confuse artefacts for M.tb cords.
With regard to heterogeneity observed for the WHO
2007 algorithm, few clinicians fully adhere to the algorithm
in practice, due to operational difficulties. Therefore,
the decision by clinicians if to treat or not for SN-PTB
is made variably. For example, of the 4 studies on the
WHO 2007 algorithm in our review, only 1 reported
results based on full adherence to all the elements of
the algorithm [8]. However, full adherence to the algorithm
in this study was quite low, ranging from 13% for the rural
site to 19% for the urban site. Based on this report, in a best
case scenario, the sensitivity of the algorithm is 95% (95%
CI; 74%-100%) while specificity is 33% (95% CI; 23%-68%).
On the other hand, based on the 3 other reports on the
WHO 2007 algorithm, the sensitivity of the algorithm in
a real world scenario is 57% (95% CI; 50%- 64%,) while
specificity is 70% (95% CI; 66%-73%). The variable ac-
cess to some of the tests in the algorithm such as chest
X-ray could explain the heterogeneity observed for the
WHO 2007 algorithm.
Our results of the GeneXpert for diagnosis of SN-PTB
are similar to those recently reported by the Cochrane
Collaboration® [49]. Both our findings and those by the
Cochrane group are however lower than what was re-
ported in another publication, where the authors found
sensitivity of GeneXpert for smear-negative PTB to be
75% and specificity 98% [50]. However, it was not clear
whether they used the random-effects model for this
subgroup analysis in their report. The random-effects
model is the recommended analytical approach for
meta-analysis since it incorporates heterogeneity among
studies as opposed to the fixed-effects model which
ignores heterogeneity [51].
Unlike in the report by the Cochrane group, where
meta-analysis for the effect of HIV on the diagnostic ac-
curacy of GeneXpert for SN-PTB could not be done, due
to the small numbers of publications, in our study we
found that the sensitivity of GeneXpert reduced from 67%
to 54% while specificity remained unchanged. This finding
was based on four studies with HIV prevalence ≥ 30%, an
HIV rate which is commonly seen in six of the nine TB
high burden countries from sub-Sahara Africa [1].
We used a comprehensive search and selection strat-
egy which has been used before [52]. Further, most in-
formation (70%) was from publications which had low
risk of bias, while all (100%), had low concerns regard-
ing applicability (Figure 6a and b and Table 3). This
implies good internal and external validity of the results
in the primary studies. We therefore believe that our
findings are robust. In addition any plausible bias is
unlikely to alter the results as the confidence intervals
for all the tests was narrow.
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Figure 5 Forest plots of sub-analysis of sensitivity and specificity of GeneXpert.
Figure 6 QUADAS-2 Results of (a) risk of bias and (b) concerns on applicability.
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Limitations
Our study had the following limitations: There were few
publications on MODS and the WHO2007 algorithm on
diagnosis of SN-PTB. Moreover a substantial number of
the publications on these two tests had to be excluded
due to lack of reported data to compute sensitivity and
specificity of the tests for diagnosis of SN-PTB. This
included 2 large landmark studies on GeneXpert for
the same reason [22,23]. The negative or positive influence
of these studies on the pooled accuracy of the tests could
therefore not be established. Further, although there was
substantial heterogeneity across all studies for the three
diagnostic methods, we did not perform a meta-regression
analysis to investigate the effects of the various charac-
teristics associated with the observed heterogeneity.
However, our primary aim was not to explore the fac-
tors that may be accountable for the differences among
studies. Besides, to achieve reliable conclusions from
such an investigation, one would need to pre-specify the
protocol of the review since explorations of heterogeneity
that are devised after heterogeneity is identified cannot be
conclusive. We did not also assess publication bias of the
studies which we meta-analyzed. This was because there
were few studies on MODS and the WHO algorithm for
such analysis [53]. In addition, despite its cited advantages
(such as being free and user friendly), the meta-disc soft-
ware which we used in our analysis is limited in some stat-
istical tests including the Egger’s test and Begg’s tests that
are recommended for assessing publication bias.
Conclusions
The GeneXpert, MODS, and the WHO algorithm have
moderate to high accuracy for the diagnosis of SN-PTB.
However, the accuracy of the tests is extremely variable.
The setting and context under which the tests are con-
ducted in addition to several other factors could explain
Table 3 QUADAS-2 results of risk of bias and concerns on applicability for each study included in the meta-analysis (n = 24)
Risk of bias Applicability concerns














Genexpert Helb [24] (+) (+) (+) (+) (+) (+) (+)
Genexpert Malbruny [25] (+) (+) (+) (+) (+) (+) (+)
Genexpert Bowles [26] (- ) ( ? ) ( ? ) ( ? ) (+) (+) (+)
Genexpert Moure [27] (+) (+) (+) (+) (+) (+) (+)
Genexpert Marlowe [28] (+) (+) (+) (+) (+) (+) (+)
Genexpert Theron [29] (+) (+) (+) (+) (+) (+) (+)
Genexpert Rachow [30] (+) (+) (+) (+) (+) (+) (+)
Genexpert Scott [31] (- ) (+) (+) (+) (+) (+) (+)
Genexpert Lawn [32] (+) (+) (+) (+) (+) (+) (+)
Genexpert Ioannidis [33] (- ) (+) (+) ( ? ) (+) (+) (+)
Genexpert Miller [34] (- ) (+) (+) ( ? ) (+) (+) (+)
Genexpert Teo [35] (- ) (+) (+) ( ? ) (+) (+) (+)
Genexpert Nicol [36] (+) (+) (+) (+) (+) (+) (+)
Genexpert Rachow [37] (+) (+) (+) (+) (+) (+) (+)
Genexpert Safianowska [38] (- ) (+) (+) ( ? ) (+) (+) (+)
MODS Arias [39] (+) (+) (+) (+) (+) (+) (+)
MODS Mashta [40] (+) (+) (+) (+) (+) (+) (+)
MODS Shah [41] (+) (+) (+) (+) (+) (+) (+)
MODS Ha DT [42] (+) (+) (+) (+) (+) (+) (+)
MODS Chaiyasirinroje [43] (+) (+) (+) (+) (+) (+) (+)
WHO2007 Wilson [44] (+) (+) (+) (+) (+) (+) (+)
WHO2007 Swai [45] (+) (+) (+) (+) (+) (+) (+)
WHO2007 Koole [46] (+) (+) (+) (+) (- ) (+) (+)
WHO2007 Alamo [8] Rural site (-) (+) (+) (+) (-) (+) (+)
WHO2007 Alamo [8] Urban site (-) (+) (+) (+) (+) (+) (+)
(+) = low. (-) = High. (?) = Unclear.
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this variability. There is therefore need to investigate these
factors further. The information from these studies would
inform the adoption and placement of these new tests.
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